Drug intelligence / Profile preview

LY3045697

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY3045697 is a potent and highly selective small-molecule inhibitor of aldosterone synthase (CYP11B2), developed to reduce aldosterone production with minimal effects on cortisol synthesis. It demonstrates rapid, dose-dependent suppression of plasma aldosterone concentrations in humans and has shown a favorable safety and tolerability profile in early clinical trials. The drug was developed by Eli Lilly and Company for potential use in conditions such as hypertension, chronic kidney disease, and disorders related to mineralocorticoid excess[1][2][3].

Targets

CYP11B2 (Cytochrome P450 11B2)

Beyond the preview

Go deeper on LY3045697.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3045697.

Explore the full profile